An Open-Label, Long-Term Safety Study of Long-acting Human Growth Hormone Somavaratan (VRS-317) in Japanese Children With Growth Hormone Deficiency

Trial Profile

An Open-Label, Long-Term Safety Study of Long-acting Human Growth Hormone Somavaratan (VRS-317) in Japanese Children With Growth Hormone Deficiency

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Growth disorders; Somatotropin deficiency
  • Focus Adverse reactions
  • Sponsors Versartis
  • Most Recent Events

    • 04 May 2017 Status changed from planning to recruiting.
    • 21 Feb 2017 According to Versartis media release, company anticipates to complete enrollment in 2H of 2017.
    • 15 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top